BioSpace News Archive

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it expect delays in enrollment in the Company’s ambulance-based PHAST-TSC phase 2 clinical trial in acute stroke due to the coronavirus.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial results for the year ended December 31, 2019 and provided a corporate update.

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today provided a corporate update and reported financial results for the full year ended December 31, 2019.

OpGen, Inc. (NASDAQ: OPGN), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, reported today its audited stand-alone financial and operating results for the three and 12 months ended December 31, 2019 and provided a business update.

Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported the initiation of three clinical studies of antolimab: a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD), a Phase 2/3 study in eosinophilic esophagitis (EoE), and a Phase 1 study of subcutaneously administered antolimab in healthy volunteers.

BiondVax Pharmaceuticals Ltd., developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the Company’s Annual General Meeting held, including the election of three new directors to the Company’s Board of Directors, namely, Dr. Yael Margolin, Mr. Adi Raviv, and Mr. Samuel Moed.

Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, is pleased to announce that a rapid test for COVID-19 created by its labs at the Center for Discovery and Innovation (CDI) has been licensed to T2 Biosystems, a Massachusetts-based leader of in-vitro diagnostics.

3M Chairman and Chief Executive Officer Mike Roman delivered the following letter to William Barr, attorney general of the United States; Larry Hogan, governor of Maryland and chair of the National Governors Association; and Tim Fox, attorney general of Montana and president of the National Association of Attorneys General, highlighting 3M’s actions to curb counterfeiting and price gouging of personal protective equipment during the COVID-19 pandemic.

Rainbow Babies and Children’s Hospital, Children’s National Hospital, and Children’s Hospital of Orange County are the first three to receive $200,000 each to assist COVID-19 testing for children with pediatric cancer

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic